Liu Dongfang 4
4 · Nuvation Bio Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Liu Dongfang
CHIEF MEDICAL OFFICER
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-11-17−15,000→ 485,000 totalExercise: $1.87Exp: 2034-02-27→ Class A Common Stock (15,000 underlying) - Exercise/Conversion
Class A Common Stock
2025-11-17$1.87/sh+15,000$28,050→ 30,000 total - Exercise/Conversion
Class A Common Stock
2025-11-19$1.87/sh+15,000$28,050→ 30,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-19−15,000→ 470,000 totalExercise: $1.87Exp: 2034-02-27→ Class A Common Stock (15,000 underlying) - Sale
Class A Common Stock
2025-11-17$4.76/sh−15,000$71,475→ 15,000 total - Sale
Class A Common Stock
2025-11-19$5.10/sh−15,000$76,553→ 18,000 total
Footnotes (4)
- [F1]Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.21. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Includes 3,000 shares acquired on November 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F4]Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.